OncoCipherPATIENT
Educational & Guideline Reference Notice: Unranked FDA-label and national guideline option categories and recruiting clinical trials for discussion with a licensed oncologist. Protocol drug dosing and autonomous treatment prescriptions are excluded.

← Non-Small Cell Lung Cancer (NSCLC) Overview

Non-Small Cell Lung Cancer (NSCLC) — All 92 Unranked Reference Options

Provenance SHA-256: e49a0a4d5ea0051f · Protocol drug dosing hard-excluded in Patient Edition.

Option / Regimen FamilyCategory & StatusCurated Source IDs
Anatomic resection and nodal assessment
Review definitive surgery for operable early NSCLC.
Local treatment
Care pathway
nci_nsclc, calgb140503
Definitive stereotactic radiation review
Review SBRT for medically inoperable, node-negative early disease.
Local treatment
Care pathway
nci_nsclc, rtog0236
Perioperative pembrolizumab plus platinum chemotherapy
Neoadjuvant platinum-based treatment followed by surgery and adjuvant immunotherapy in the studied resectable setting.
Systemic therapy
FDA-approved
peri_pembro, kn671_5y
Perioperative nivolumab plus platinum chemotherapy
Neoadjuvant platinum-based treatment followed by surgery and adjuvant immunotherapy in the studied resectable setting.
Systemic therapy
FDA-approved
peri_nivo, cm77t, cm77t_ctgov
Perioperative durvalumab plus platinum chemotherapy
Neoadjuvant platinum-based treatment followed by surgery and adjuvant immunotherapy in the studied resectable setting.
Systemic therapy
FDA-approved
peri_durva, aegean
Adjuvant platinum-based chemotherapy
Review adjuvant platinum after complete resection in the appropriate stage and treatment sequence.
Systemic therapy
Care pathway
nci_nsclc, lace
Adjuvant osimertinib
EGFR exon 19 deletion or L858R after complete resection; chemotherapy decision remains separate.
Systemic therapy
FDA-approved
tagrisso, adaura, tagrisso_coverage_20261109
Adjuvant alectinib
ALK-positive disease after complete resection meeting the tumor-size or nodal criterion.
Systemic therapy
FDA-approved
adj_alectinib, alecensa, alina, alecensa_coverage_20261109, alina_ctgov, elevate_2026
Adjuvant pembrolizumab after platinum
Postoperative immunotherapy after complete resection and platinum, without prior neoadjuvant systemic therapy.
Systemic therapy
FDA-approved
adj_pembro
Adjuvant atezolizumab after platinum
PD-L1-positive resected stage II–IIIA disease after platinum chemotherapy.
Systemic therapy
FDA-approved
adj_atezo
Concurrent platinum chemoradiation
Multidisciplinary definitive treatment for unresectable stage III NSCLC.
Systemic therapy
Care pathway
nci_nsclc
Sequential platinum chemoradiation
Multidisciplinary definitive treatment for unresectable stage III NSCLC.
Systemic therapy
Care pathway
nci_nsclc
Durvalumab after concurrent chemoradiation
Consolidation after concurrent platinum chemoradiation without progression.
Systemic therapy
FDA-approved
imfinzi, pacific5
Osimertinib after chemoradiation
EGFR exon 19 deletion or L858R disease without progression after definitive platinum chemoradiation.
Systemic therapy
FDA-approved
laura, laura_updated_2026
Osimertinib
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA-approved
tagrisso, flaura2_os, tagrisso_coverage_20261109
Osimertinib plus platinum/pemetrexed
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA-approved
osi_chemo, pemetrexed_label, flaura2_os
Amivantamab plus lazertinib
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA-approved
ami_laz, mariposa_os, rybrevant_faspro_spl
Amivantamab plus carboplatin/pemetrexed after EGFR TKI
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA-approved
ami_post, pemetrexed_label, rybrevant_faspro_spl
Datopotamab deruxtecan after EGFR therapy and platinum
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA accelerated approval
dato
Amivantamab plus carboplatin/pemetrexed
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA-approved
ami_ex20, pemetrexed_label, rybrevant_faspro_spl
Amivantamab after platinum
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA-approved
ami_ex20, chrysalis, rybrevant_faspro_spl
Sunvozertinib after platinum
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA accelerated approval
sunvo
Alectinib
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA-approved
alecensa, alex, alecensa_coverage_20261109, alex_final_os_2025
Lorlatinib
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA-approved
lorbrena, crown5
Ensartinib
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA-approved
ensartinib, exalt3
Repotrectinib
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA-approved
repo, trident1
Taletrectinib
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA-approved
talet
Zidesamtinib after a ROS1 inhibitor
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA-approved
zides
Selpercatinib
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA-approved
retevmo, libretto431, libretto431_pmc
Tepotinib
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA-approved
tepo, vision
Encorafenib plus binimetinib
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA-approved
enco, pharos, pharos_os_2025
Zongertinib
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA accelerated approval
zong
Sevabertinib
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA accelerated approval
seva
Trastuzumab deruxtecan after prior systemic treatment
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA-approved
tdxd, dl02, enhertu_label_o12
Sotorasib
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA accelerated approval
lumakras, cb200, cb200_ctgov, krascendo1_2026
Adagrasib
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA accelerated approval
krazati, krystal12, krystal12_ctgov, krascendo1_2026
Larotrectinib for an NTRK fusion
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA-approved
laro, laro_lung
Zenocutuzumab after prior treatment
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapy
FDA accelerated approval
zeno
Telisotuzumab vedotin for high c-MET expression
Previously treated nonsquamous NSCLC meeting the exact approved c-MET protein-expression threshold.
Systemic therapy
FDA accelerated approval
teliso
Pembrolizumab plus pemetrexed/platinum
First-line chemoimmunotherapy after molecular review in nonsquamous NSCLC.
Systemic therapy
FDA-approved
kn189, nci_nsclc, pemetrexed_label, kn189_5y, persee_primary_20261025, persee_registry_20261109
Pembrolizumab plus carboplatin/taxane
First-line chemoimmunotherapy after molecular review in squamous NSCLC.
Systemic therapy
FDA-approved
kn407, nci_nsclc, kn407_5y, persee_primary_20261025, persee_registry_20261109
Pembrolizumab monotherapy for high PD-L1
Review a chemotherapy-free first-line option in driver-negative, high-PD-L1 disease.
Systemic therapy
FDA-approved
nci_nsclc, kn024_5y, persee_primary_20261025, persee_registry_20261109
Platinum-doublet review when immunotherapy is unsuitable
Review histology-appropriate cytotoxic treatment when a documented immunotherapy concern prevents an IO pathway.
Systemic therapy
Care pathway
nci_nsclc
SCLC resection followed by systemic-treatment review
Rare early node-negative SCLC requires invasive staging and multidisciplinary surgical review.
Local treatment
Care pathway
nci_sclc
SCLC stereotactic radiation plus chemotherapy review
Early node-negative medically inoperable SCLC may be reviewed for SBRT and systemic chemotherapy.
Local treatment
Care pathway
nci_sclc
Concurrent platinum/etoposide chemoradiation
Combined systemic and thoracic treatment for eligible limited-stage SCLC.
Systemic therapy
Care pathway
nci_sclc
Durvalumab after limited-stage chemoradiation
Limited-stage SCLC without progression after concurrent platinum chemoradiation.
Systemic therapy
FDA-approved
adriatic, adriatic_primary
Atezolizumab plus carboplatin/etoposide
First-line extensive-stage SCLC induction followed by maintenance review.
Systemic therapy
FDA-approved
im133, nci_sclc
Durvalumab plus platinum/etoposide
First-line extensive-stage SCLC with cisplatin or carboplatin plus etoposide.
Systemic therapy
FDA-approved
imfinzi, caspian3
Atezolizumab maintenance
Continue maintenance after the matching atezolizumab/carboplatin/etoposide induction.
Systemic therapy
FDA-approved
im133, imforte, imforte_primary
Lurbinectedin plus atezolizumab maintenance
Maintenance intensification after matching induction without progression.
Systemic therapy
FDA-approved
imforte, imforte_primary
Durvalumab maintenance
Continue maintenance only after the matching durvalumab-containing induction.
Systemic therapy
FDA-approved
imfinzi
Tarlatamab after platinum progression
Review DLL3-directed treatment after platinum-based chemotherapy progression.
Systemic therapy
FDA-approved
tarlatamab, imdelltra_label_v8
Relapsed SCLC chemotherapy review
Grouped review of other salvage chemotherapy in context of interval, prior drugs and fitness. Topotecan and platinum rechallenge are shown as their own options; lurbinectedin alone is shown separately as off-label because its relapsed small-cell indication left the label in 09/2026.
Systemic therapy
Care pathway
nci_sclc, tarlatamab
Neoadjuvant-only nivolumab plus platinum chemotherapy
CheckMate816: neoadjuvant treatment then planned surgery, without automatically adding postoperative nivolumab.
Source-supported additional alternative
FDA-approved neoadjuvant pathway
cm816_os, opdivo_neo, cm816_registry
Osimertinib plus savolitinib after osimertinib (SAFFRON)
MET-selected post-osimertinib discussion requiring exact post-progression tissue criteria and access review.
Source-supported additional alternative
Investigational US pathway; no FDA approval asserted
saffron, saffron_registry
Tarlatamab plus durvalumab maintenance (DeLLphi-305)
First-line maintenance only after matching durvalumab induction without progression; not the post-platinum relapse indication.
Source-supported additional alternative
Off-label US maintenance pathway
d305, d305_registry, tarlatamab
Brigatinib
Source-qualified alternative for the specified molecular and treatment setting.
Systemic therapy
FDA-approved
brigatinib_label_i7
Capmatinib
Source-qualified alternative for the specified molecular and treatment setting.
Systemic therapy
FDA-approved
capmatinib_label_i7
Dabrafenib plus trametinib
Source-qualified alternative for the specified molecular and treatment setting.
Systemic therapy
FDA-approved
dabrafenib_trametinib_label_i7
Lorlatinib after ALK-inhibitor treatment
Source-qualified alternative for the specified molecular and treatment setting.
Systemic therapy
FDA-approved
lorlatinib_post_alk_label_i7
Osimertinib for EGFR T790M after an earlier EGFR inhibitor
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
tagrisso_label_o12
Repotrectinib after a ROS1 inhibitor
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
augtyro_label_o12
Taletrectinib after a ROS1 inhibitor
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
ibtrozi_label_o12
Entrectinib
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
rozlytrek_label_o12
Crizotinib (ROS1-positive)
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
xalkori_label_o12
Zongertinib after earlier treatment
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA accelerated approval
hernexeos_label_o12
Sevabertinib after earlier treatment
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA accelerated approval
hyrnuo_label_o12
Docetaxel after platinum chemotherapy
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
docetaxel_label_o12
Ramucirumab plus docetaxel after platinum chemotherapy
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
cyramza_label_o12, docetaxel_label_o12
Pemetrexed alone after earlier chemotherapy
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
alimta_label_o12
Platinum plus pemetrexed after a targeted drug
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
alimta_label_o12
Atezolizumab + bevacizumab + paclitaxel + carboplatin
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
tecentriq_label_o12, avastin_label_o12
Atezolizumab + nab-paclitaxel + carboplatin
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
tecentriq_label_o12, abraxane_label_o12
Nivolumab + ipilimumab + 2 cycles of platinum-doublet chemotherapy
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
opdivo_label_o12, yervoy_label_o12
Nivolumab + ipilimumab (PD-L1 at least 1%)
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
opdivo_label_o12, yervoy_label_o12
Cemiplimab + platinum-based chemotherapy
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
libtayo_label_o12
Cemiplimab alone (PD-L1 at least 50%)
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
libtayo_label_o12
Atezolizumab alone (high PD-L1)
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
tecentriq_label_o12
Durvalumab + tremelimumab + platinum-based chemotherapy
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
imfinzi_label_o12, imjudo_label_o12
Pralsetinib
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
gavreto_label_o12
Topotecan (into a vein) for platinum-sensitive relapse
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
hycamtin_inj_label_o12
Topotecan (capsules) for relapse after a response
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
hycamtin_caps_label_o12
Carboplatin + etoposide rechallenge for sensitive relapse (off-label)
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
Off-label US pathway; supported by one randomized phase 3 trial (162 patients)
pm_32888454, etoposide_label_o12, carboplatin_label_o12, pdq_sclc
Lurbinectedin alone for relapse (off-label since 09/2026)
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
Off-label US pathway; the relapsed small-cell indication left the label in 09/2026
pm_32224306, zepzelca_label_o12, lurbi_b005_ctgov
Alectinib after another ALK inhibitor
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
alecensa_label_o12
Brigatinib after another ALK inhibitor
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
alunbrig_label_o12
Selpercatinib after another RET inhibitor
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
retevmo_label_o12
Pralsetinib after another RET inhibitor
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
gavreto_label_o12
Capmatinib after another MET inhibitor
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
tabrecta_label_o12
Tepotinib after another MET inhibitor
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
tepmetko_label_o12
Dabrafenib + trametinib after another BRAF/MEK pair
Label indication met by the recorded setting; shown unranked beside the other options.
Systemic therapy
FDA-approved
tafinlar_label_o12